Screener
Travere Therapeutics, Inc. TVTX Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$34.8M-173% | -$37.1M+10.0% | —— | $25.71M+147% | -$12.76M+81.9% | ||
| $4.23M-69.8% | $25.21M+96.9% | $18.14M+50.0% | $15.79M+40.5% | $14.02M+35.5% | ||
| $21.79M+105% | $16.15M+40.5% | $11.46M+24.4% | $11.26M+40.4% | $10.65M+7.4% | ||
| $58.07M— | -$40.37M+4.3% | $60.68M+270% | —— | —— | ||
| -$206.29M-4,353% | $21.55M-47.8% | —— | $86.59M+87.7% | $4.85M-83.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $68.9M— | —— | ||
| $187.52M+12,613% | $4.2M+13.1% | —— | -$65.34M-142,141% | $1.48M+88.6% | ||
| $39.37M+197% | -$14.67M-536% | —— | $35.78M— | $13.26M+221% |
FAQ
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
